Sirtuin 6: A potential therapeutic target for cardiovascular diseases

• Published in: Pharmacological research 2021-01, Vol.163, p.105214-105214, Article 105214
• Main Authors: Saiyang, Xie, Deng, Wei, Qizhu, Tang
• Format: Article
• Language: English
• Subjects: Cardiac remodeling; Cardiovascular diseases; Heart failure; Sirtuin 6
• ISSN: 1043-6618; 1096-1186
• DOI: 10.1016/j.phrs.2020.105214

SIRT6 plays a critical role in the occurrence and development of CVDs. SIRT6 inhibits cardiomyocyte hypertrophy, transformation of fibroblasts, formation of atheromatous plaque and infiltration of inflammatory cells. SIRT6 ameliorates cardiac remodeling and atherosclerosis, and prevents the occurrence and development of CVDs. [Display omitted] •We systemically summarized the role of SIRT6 in detail, which promoted the understanding of SIRT6.•In current document, we summarized the clinical trials associated with SIRT6 modulation so far, which promoted the clinical application of SIRT6.•We demonstrate the unique role of SIRT6 in regulating CVDs and make an expectation that SIRT6 modulation is endowed with a promising future.•We minutely limned the molecular mechanism of SIRT6 in cardiovascular diseases in the present review for the first time, by which we provided the rational evidence for the clinical application of SIRT6 modulation. Cardiovascular diseases (CVDs) are serious diseases endangering human health due to high morbidity and mortality worldwide, and numerous signal molecules are involved in this pathological process. As a member of the Sirtuin family NAD +-dependent deacetylases, indeed, Sirtuin 6 (SIRT6) plays an important role in regulating biological homeostasis, longevity, and various diseases. More importantly, SIRT6 performs as an indispensable role in glucose and lipid metabolism, inflammation and genomic stability for the occurrence and development of various CVDs. Recent advances: among sirtuins, SIRT6 was frequently unveiled thanks for its protective roles against heart failure, cardiovascular remodeling and atherosclerosis, and identified as an essential intervention target of CVDs, bringing SIRT6 into the focus of clinical interest. Herein, we provide an overview of the current molecular mechanism through which SIRT6 regulates CVDs, and we highlight a potential therapeutic target for CVDs.